A Phase 2 interventional study of pemigatinib and pemigatinib in UC (Urothelial Cancer), sponsored by Incyte Corporation. Completed at 96 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Carcinoma, Transitional Cell by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Carcinoma, Transitional Cell · Incyte Corporation.
Among the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation, this one has the largest enrollment, is one of 5 that started in 2017, is one of 3 in phase 2, and was the 1st registered.
632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →None of the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation is open now. The open studies under Carcinoma, Transitional Cell, anywhere →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 1
First in 2017; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 263 is above the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 46 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Carcinoma, Transitional Cell by Incyte Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemigatinib in subjects with FGFR3 mutations or fusions.
Drug: pemigatinib
Pemigatinib in subjects with FGFR3 mutations or fusions.
Drug: pemigatinib
Pemigatinib in subjects with other FGF/FGFR alterations.
Drug: pemigatinib
Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
Also known as: INCB054828
Pemigatinib once a day by mouth continuously.
Also known as: INCB054828
Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
Time frame: up to 1138 days
ORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
Time frame: up to 817 days
ORR in Participants With All Other FGF/FGFR Alterations
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
Time frame: up to 1198 days
ORR in All Participants on an ID or CD Regimen in Combined Cohorts
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
Time frame: up to 1198 days
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.
Time frame: up to approximately 25 weeks
Progression-free Survival (PFS)
PFS was defined as the length of time from the start of the study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.
Time frame: up to 1138 days
Duration of Response (DOR)
DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed
Time frame: up to 1075 days
Overall Survival
Overall survival was defined as the length of time from the start of the study drug (Day 1) until the date of death due to any cause.
Time frame: up to 1610 days
| Milestone | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| Started | 103 | 44 | 9 | 101 | 3 |
| Completed | 10 | 2 | 1 | 13 | 1 |
| Not completed | 93 | 42 | 8 | 88 | 2 |
| Withdrew: Progressive disease | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 87 | 36 | 8 | 81 | 2 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 3 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 2 | 0 |
| Withdrew: Captured as other | 2 | 0 | 0 | 1 | 0 |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) or partial response (PR) at any post-Baseline visit prior to first progressive disease (PD), per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
| percentage of participants | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen | — | — | — | 17.8 (10.92 to 26.70) | — |
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
| percentage of participants | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| ORR in Participants With FGFR3 Mutations or Fusions on an ID Regimen | 23.3 (15.54 to 32.66) | — | — | — | — |
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
| percentage of participants | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| ORR in Participants With All Other FGF/FGFR Alterations | — | 6.8 (1.43 to 18.66) | — | — | — |
ORR was defined as the percentage of participants with a best overall response of CR or PR at any post-Baseline visit prior to first PD, per RECIST v1.1. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed.
| percentage of participants | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD | Cohort A-ID + Cohort B-ID | Cohort A-ID + Cohort A-CD | Cohort A-ID + Cohort B-ID + Cohort A-CD |
|---|---|---|---|---|---|---|---|---|
| ORR in All Participants on an ID or CD Regimen in Combined Cohorts | — | — | — | — | — | 18.4 (12.47 to 25.59) | 20.6 (15.26 to 26.79) | 18.1 (13.55 to 23.52) |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurred after a participant provided informed consent. Abnormal laboratory values or test results occurring after informed consent constituted AEs only if they induced clinical signs or symptoms, were considered clinically meaningful, required therapy (e.g., hematologic abnormality that required transfusion), or required changes in the study drug(s). A TEAE was any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug and within 30 days of the last dose of study drug.
| Participants | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 103 | 44 | 9 | 100 | 3 |
PFS was defined as the length of time from the start of the study drug (Day 1) to the earlier of death or disease progression by RECIST v1.1, as assessed by the independent centralized radiological review committee.
| months | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | 4.27 (3.91 to 6.05) | 2.04 (1.87 to 2.17) | — | 4.04 (3.45 to 4.17) | — |
DOR was defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of death or first overall response of PD occurring after the first overall response contributing to the objective response. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \<10 millimeters (mm). PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. Response was based on review of scans by an independent centralized radiological review committee. Response was confirmed
| months | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| Duration of Response (DOR) | 6.21 (4.60 to 7.95) | 10.02 (8.38 to NA) | — | 6.23 (4.14 to 8.25) | — |
Overall survival was defined as the length of time from the start of the study drug (Day 1) until the date of death due to any cause.
| months | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| Overall Survival | 8.90 (7.46 to 15.18) | 9.13 (5.52 to 17.05) | — | 6.80 (5.26 to 9.10) | — |
Collected over Adverse events were assessed for up to approximately 25 weeks; All-cause Mortality was assessed for up to 1610 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A-ID: FGFR3 Mutations or Fusions | 88/103 (85.4%) | 45/103 (43.7%) | 101/103 (98.1%) |
| Cohort B-ID: All Other FGF/FGFR Alterations | 39/44 (88.6%) | 26/44 (59.1%) | 43/44 (97.7%) |
| Other-ID | 8/9 (88.9%) | 3/9 (33.3%) | 9/9 (100%) |
| Cohort A-CD: FGFR3 Mutations or Fusions | 83/101 (82.2%) | 48/101 (47.5%) | 99/101 (98%) |
| Other-CD | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/103 | 1/44 | 0/9 | 2/101 | 1/3 |
| Back painMusculoskeletal and connective tissue disorders | 2/103 | 2/44 | 0/9 | 1/101 | 1/3 |
| HyponatraemiaMetabolism and nutrition disorders | 0/103 | 2/44 | 0/9 | 1/101 | 1/3 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/103 | 0/44 | 1/9 | 0/101 | 0/3 |
| HaematuriaRenal and urinary disorders | 4/103 | 1/44 | 1/9 | 0/101 | 0/3 |
| PyrexiaGeneral disorders | 1/103 | 1/44 | 1/9 | 1/101 | 0/3 |
| Spinal cord infectionInfections and infestations | 0/103 | 0/44 | 1/9 | 0/101 | 0/3 |
| Acute kidney injuryRenal and urinary disorders | 3/103 | 4/44 | 0/9 | 2/101 | 0/3 |
| Urinary tract infectionInfections and infestations | 6/103 | 1/44 | 0/9 | 8/101 | 0/3 |
| ConstipationGastrointestinal disorders | 2/103 | 3/44 | 0/9 | 0/101 | 0/3 |
| Event | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD |
|---|---|---|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 49/103 | 16/44 | 7/9 | 38/101 | 1/3 |
| Dry mouthGastrointestinal disorders | 33/103 | 13/44 | 7/9 | 39/101 | 1/3 |
| Abdominal painGastrointestinal disorders | 20/103 | 11/44 | 1/9 | 7/101 | 2/3 |
| DiarrhoeaGastrointestinal disorders | 53/103 | 19/44 | 6/9 | 34/101 | 2/3 |
| Dry skinSkin and subcutaneous tissue disorders | 21/103 | 6/44 | 4/9 | 22/101 | 2/3 |
| DysgeusiaNervous system disorders | 32/103 | 9/44 | 6/9 | 31/101 | 1/3 |
| HyperphosphataemiaMetabolism and nutrition disorders | 35/103 | 13/44 | 4/9 | 56/101 | 2/3 |
| StomatitisGastrointestinal disorders | 48/103 | 13/44 | 3/9 | 45/101 | 1/3 |
| ConstipationGastrointestinal disorders | 36/103 | 11/44 | 4/9 | 33/101 | 1/3 |
| Decreased appetiteMetabolism and nutrition disorders | 32/103 | 11/44 | 4/9 | 29/101 | 0/3 |
| Age, Continuous(years) | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD | Total |
|---|---|---|---|---|---|---|
| Mean | 67.6 ± 9.09 | 65.1 ± 10.83 | 69.3 ± 7.98 | 68.5 ± 9.39 | 60.3 ± 9.02 | 67.5 ± 9.53 |
| Sex: Female, Male(Participants) | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD | Total |
|---|---|---|---|---|---|---|
| Female | 29 | 14 | 1 | 23 | 1 | 68 |
| Male | 74 | 30 | 8 | 78 | 2 | 192 |
| Race/Ethnicity, Customized(Participants) | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD | Total |
|---|---|---|---|---|---|---|
| White | 64 | 29 | 6 | 63 | 2 | 164 |
| Black or African-American | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 2 | 2 | 0 | 12 | 1 | 17 |
| Turkish | 1 | 0 | 0 | 0 | 0 | 1 |
| Persian | 0 | 0 | 1 | 0 | 0 | 1 |
| Unknown or Not Reported | 30 | 13 | 1 | 22 | 0 | 66 |
| Missing | 6 | 0 | 0 | 4 | 0 | 10 |
| Race/Ethnicity, Customized(Participants) | Cohort A-ID: FGFR3 Mutations or Fusions | Cohort B-ID: All Other FGF/FGFR Alterations | Other-ID | Cohort A-CD: FGFR3 Mutations or Fusions | Other-CD | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 2 | 0 | 3 |
| Not Hispanic or Latino | 64 | 32 | 7 | 66 | 2 | 171 |
| Not Reported | 23 | 11 | 2 | 22 | 1 | 59 |
| Unknown | 5 | 1 | 0 | 3 | 0 | 9 |
| Captured as Other | 5 | 0 | 0 | 6 | 0 | 11 |
| Missing | 5 | 0 | 0 | 2 | 0 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jan 2017 to primary completion in Feb 2022, 60 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's 60 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib
Carcinoma, Transitional Cell →